Q-omics provides the consensus-scored OR51B6 profile across patient tissues and cancer cell-line models. OR51B6 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, OR51B6 is differentially expressed in 1, with the highest sampling consensus in THCA. Additionally, OR51B6 RNA expression shows 8,090 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, THCA, and TGCT as cancer lineages where OR51B6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR51B6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR51B6 survival associations across molecular data types. OR51B6 RNA expression shows survival associations in the most cancer types (8), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR51B6 RNA expression–survival associations across cancer types. High OR51B6 expression shows unfavorable associations in UCEC, LGG, LIHC, TGCT and COAD, but favorable associations in OV. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for OR51B6 RNA expression.
This table summarizes OR51B6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for OR51B6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR51B6 shows lower tumor expression in THCA. The THCA box plot shows higher OR51B6 RNA expression in normal versus tumor tissue (log2 FC = −0.013, t-test p = .039).
This table shows molecular features associated with OR51B6 in patient tissues and cancer cell lines. In patient samples, OR51B6 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, OR51B6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BREAST.
